REPLIMUNE GROUP INC (REPL) Stock Fundamental Analysis

NASDAQ:REPL • US76029N1063

8.55 USD
+0.51 (+6.34%)
At close: Feb 19, 2026
8.28 USD
-0.27 (-3.16%)
After Hours: 2/19/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

REPL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. REPL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. REPL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year REPL has reported negative net income.
  • REPL had a negative operating cash flow in the past year.
  • In the past 5 years REPL always reported negative net income.
  • REPL had a negative operating cash flow in each of the past 5 years.
REPL Yearly Net Income VS EBIT VS OCF VS FCFREPL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M -250M

1.2 Ratios

  • The Return On Assets of REPL (-94.38%) is worse than 73.90% of its industry peers.
  • REPL has a worse Return On Equity (-149.55%) than 63.72% of its industry peers.
Industry RankSector Rank
ROA -94.38%
ROE -149.55%
ROIC N/A
ROA(3y)-38.68%
ROA(5y)-31.31%
ROE(3y)-49.49%
ROE(5y)-38.68%
ROIC(3y)N/A
ROIC(5y)N/A
REPL Yearly ROA, ROE, ROICREPL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10 -20 -30 -40 -50

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for REPL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
REPL Yearly Profit, Operating, Gross MarginsREPL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • REPL has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, REPL has more shares outstanding
  • The debt/assets ratio for REPL has been reduced compared to a year ago.
REPL Yearly Shares OutstandingREPL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
REPL Yearly Total Debt VS Total AssetsREPL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -4.15, we must say that REPL is in the distress zone and has some risk of bankruptcy.
  • REPL has a Altman-Z score of -4.15. This is comparable to the rest of the industry: REPL outperforms 42.23% of its industry peers.
  • REPL has a Debt/Equity ratio of 0.33. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.33, REPL is doing worse than 67.95% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Altman-Z -4.15
ROIC/WACCN/A
WACCN/A
REPL Yearly LT Debt VS Equity VS FCFREPL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 5.60 indicates that REPL has no problem at all paying its short term obligations.
  • The Current ratio of REPL (5.60) is comparable to the rest of the industry.
  • REPL has a Quick Ratio of 5.60. This indicates that REPL is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 5.60, REPL is in the better half of the industry, outperforming 60.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.6
Quick Ratio 5.6
REPL Yearly Current Assets VS Current LiabilitesREPL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • REPL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.05%.
EPS 1Y (TTM)-12.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 16.59% on average over the next years. This is quite good.
  • Based on estimates for the next years, REPL will show a very strong growth in Revenue. The Revenue will grow by 175.20% on average per year.
EPS Next Y-19.28%
EPS Next 2Y15.22%
EPS Next 3Y10.12%
EPS Next 5Y16.59%
Revenue Next Year-100%
Revenue Next 2Y476.05%
Revenue Next 3Y307.89%
Revenue Next 5Y175.2%

3.3 Evolution

REPL Yearly Revenue VS EstimatesREPL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2025 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
REPL Yearly EPS VS EstimatesREPL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • REPL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year REPL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
REPL Price Earnings VS Forward Price EarningsREPL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
REPL Per share dataREPL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.22%
EPS Next 3Y10.12%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for REPL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

REPLIMUNE GROUP INC

NASDAQ:REPL (2/19/2026, 8:00:01 PM)

After market: 8.28 -0.27 (-3.16%)

8.55

+0.51 (+6.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-03
Earnings (Next)05-20
Inst Owners106.77%
Inst Owner Change2.21%
Ins Owners2.43%
Ins Owner Change1.54%
Market Cap705.97M
Revenue(TTM)N/A
Net Income(TTM)-314.85M
Analysts82.86
Price Target12.82 (49.94%)
Short Float %19.2%
Short Ratio11.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.43%
Min EPS beat(2)-12.32%
Max EPS beat(2)15.18%
EPS beat(4)1
Avg EPS beat(4)-4.83%
Min EPS beat(4)-15.38%
Max EPS beat(4)15.18%
EPS beat(8)3
Avg EPS beat(8)-1.57%
EPS beat(12)5
Avg EPS beat(12)0.68%
EPS beat(16)7
Avg EPS beat(16)-0.01%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)18.32%
EPS NQ rev (1m)11.76%
EPS NQ rev (3m)-0.13%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.66%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.35
P/tB 3.35
EV/EBITDA N/A
EPS(TTM)-3.44
EYN/A
EPS(NY)-2.06
Fwd EYN/A
FCF(TTM)-3.42
FCFYN/A
OCF(TTM)-3.36
OCFYN/A
SpS0
BVpS2.55
TBVpS2.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -94.38%
ROE -149.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.68%
ROA(5y)-31.31%
ROE(3y)-49.49%
ROE(5y)-38.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 156.81%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.6
Quick Ratio 5.6
Altman-Z -4.15
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)165.62%
Cap/Depr(5y)149.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.53%
EPS Next Y-19.28%
EPS Next 2Y15.22%
EPS Next 3Y10.12%
EPS Next 5Y16.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y476.05%
Revenue Next 3Y307.89%
Revenue Next 5Y175.2%
EBIT growth 1Y-35.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.96%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-60.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.2%
OCF growth 3YN/A
OCF growth 5YN/A

REPLIMUNE GROUP INC / REPL FAQ

What is the fundamental rating for REPL stock?

ChartMill assigns a fundamental rating of 2 / 10 to REPL.


What is the valuation status of REPLIMUNE GROUP INC (REPL) stock?

ChartMill assigns a valuation rating of 0 / 10 to REPLIMUNE GROUP INC (REPL). This can be considered as Overvalued.


What is the profitability of REPL stock?

REPLIMUNE GROUP INC (REPL) has a profitability rating of 0 / 10.


Can you provide the financial health for REPL stock?

The financial health rating of REPLIMUNE GROUP INC (REPL) is 4 / 10.